The aberrant methylation in specific CpG sites in MSH2, PALB2, FANCI, and EPCAM could result from changes in the DNA of peripheral blood leukocyte subpopulations, influenced by the tumor microenvironment, and the immune response at systemic level (Fig. 7c)43. Here, MSH2 is linked to neoplasm.